| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 5030 | 2017 |
| Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The lancet oncology 20 (1), 31-42, 2019 | 1988 | 2019 |
| Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study M Crump, SS Neelapu, U Farooq, E Van Den Neste, J Kuruvilla, J Westin, ... Blood, The Journal of the American Society of Hematology 130 (16), 1800-1808, 2017 | 1531 | 2017 |
| Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... New England Journal of Medicine 386 (7), 640-654, 2022 | 936 | 2022 |
| Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research analysis C Casulo, JW Friedberg, KW Ahn, C Flowers, A DiGilio, SM Smith, ... Biology of Blood and Marrow Transplantation 24 (6), 1163-1171, 2018 | 153 | 2018 |
| Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma JR Westin, OO Oluwole, MJ Kersten, DB Miklos, MA Perales, A Ghobadi, ... New England Journal of Medicine, 2023 | 152 | 2023 |
| Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma SS Neelapu, CA Jacobson, A Ghobadi, DB Miklos, LJ Lekakis, ... Blood, The Journal of the American Society of Hematology 141 (19), 2307-2315, 2023 | 145 | 2023 |
| Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation TS Fenske, KW Ahn, TM Graff, A DiGilio, Q Bashir, RT Kamble, E Ayala, ... British journal of haematology 174 (2), 235-248, 2016 | 143 | 2016 |
| Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma OO Oluwole, K Bouabdallah, J Muñoz, S De Guibert, JM Vose, NL Bartlett, ... British journal of haematology 194 (4), 690-700, 2021 | 128 | 2021 |
| Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma G Talamo, U Farooq, M Zangari, J Liao, NG Dolloff, TP Loughran Jr, ... Clinical Lymphoma Myeloma and Leukemia 10 (6), 464-468, 2010 | 127 | 2010 |
| Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma TC El-Galaly, CY Cheah, MD Bendtsen, GS Nowakowski, R Kansara, ... European Journal of Cancer 93, 57-68, 2018 | 117 | 2018 |
| Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials MJ Maurer, H Ghesquières, BK Link, JP Jais, TM Habermann, ... Journal of clinical oncology 36 (16), 1603, 2018 | 113 | 2018 |
| Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers AM Evens, A Danilov, D Jagadeesh, A Sperling, SH Kim, R Vaca, C Wei, ... Blood, The Journal of the American Society of Hematology 137 (3), 374-386, 2021 | 96 | 2021 |
| Graft versus host disease after liver transplantation in adults: a case series, review of literature, and an approach to management AR Murali, S Chandra, Z Stewart, BR Blazar, U Farooq, MN Ince, ... Transplantation 100 (12), 2661-2670, 2016 | 96 | 2016 |
| Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 Zuma-1 SS Neelapu, FL Locke, NL Bartlett, L Lekakis, D Miklos, CA Jacobson, ... Blood, The Journal of the American Society of Hematology 128 (22), LBA-6-LBA-6, 2016 | 77 | 2016 |
| Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure SM Smith, J Godfrey, KW Ahn, A DiGilio, S Ahmed, V Agrawal, ... Cancer 124 (12), 2541-2551, 2018 | 75 | 2018 |
| Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) cohort study JR Cerhan, BK Link, TM Habermann, MJ Maurer, AL Feldman, SI Syrbu, ... International journal of epidemiology 46 (6), 1753-1754i, 2017 | 71 | 2017 |
| Clinical heterogeneity of diffuse large B cell lymphoma following failure of front‐line immunochemotherapy U Farooq, MJ Maurer, CA Thompson, G Thanarajasingam, DJ Inwards, ... British journal of haematology 179 (1), 50-60, 2017 | 71 | 2017 |
| Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) Cohort Study JR Cerhan, BK Link, TM Habermann, MJ Maurer, AL Feldman, SI Syrbu, ... International journal of epidemiology 46 (6), 1753-1754i, 2017 | 71 | 2017 |
| Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, PM Reagan, DB Miklos, ... Blood advances 5 (20), 4149-4155, 2021 | 67 | 2021 |
James CerhanMayo Clinic在 mayo.edu 的电子邮件经过验证
